These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 12511894)

  • 1. Antisoma-Roche deal--a new kind of buyout?
    Mitchell P
    Nat Biotechnol; 2003 Jan; 21(1):3. PubMed ID: 12511894
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyseq-Variagenics merger signals end of the line.
    Hodgson J
    Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
    [No Abstract]   [Full Text] [Related]  

  • 3. Biotechs hold their own in shifting industry.
    Mitchell P
    Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
    [No Abstract]   [Full Text] [Related]  

  • 4. UK industry consolidation is slow despite big merger.
    Mitchell P
    Nat Biotechnol; 2003 Mar; 21(3):215. PubMed ID: 12610553
    [No Abstract]   [Full Text] [Related]  

  • 5. UK bidding war amidst merger mania.
    Mitchell P
    Nat Biotechnol; 2003 Apr; 21(4):343-4. PubMed ID: 12665805
    [No Abstract]   [Full Text] [Related]  

  • 6. UK biotech sector loses flagship PowderJect to Chiron.
    Mitchell P
    Nat Biotechnol; 2003 Jul; 21(7):717. PubMed ID: 12833073
    [No Abstract]   [Full Text] [Related]  

  • 7. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 8. Is Elan a turnaround?
    Jacobs T
    Nat Biotechnol; 2003 Sep; 21(9):985. PubMed ID: 12949557
    [No Abstract]   [Full Text] [Related]  

  • 9. Roche vows to keep Genentech culture.
    Hayden EC
    Nature; 2009 Mar; 458(7236):270. PubMed ID: 19295574
    [No Abstract]   [Full Text] [Related]  

  • 10. Changing partners.
    Nat Biotechnol; 2002 Sep; 20(9):855. PubMed ID: 12205487
    [No Abstract]   [Full Text] [Related]  

  • 11. Splurge or merge?
    Jacobs T
    Nat Biotechnol; 2003 May; 21(5):485. PubMed ID: 12721563
    [No Abstract]   [Full Text] [Related]  

  • 12. Should platform companies move toward products?
    Ratner M
    Nat Biotechnol; 1999 Jan; 17(1):16-7. PubMed ID: 9920255
    [No Abstract]   [Full Text] [Related]  

  • 13. Small company mergers--good for whom?
    Maybeck V; Bains W
    Nat Biotechnol; 2006 Nov; 24(11):1343-8. PubMed ID: 17093475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Market watch: Biopharma deal-making in 2014: a record year for M&A value.
    Micklus A; Muntner S
    Nat Rev Drug Discov; 2015 Feb; 14(2):84-5. PubMed ID: 25633786
    [No Abstract]   [Full Text] [Related]  

  • 15. Bioentrepreneurship around the world.
    Persidis A
    Nat Biotechnol; 1998 May; 16 Suppl():3-4. PubMed ID: 9591247
    [No Abstract]   [Full Text] [Related]  

  • 16. Biotech's wonder ride.
    Rynecki D
    Fortune; 2000 Mar; 141(5):435-6. PubMed ID: 10788046
    [No Abstract]   [Full Text] [Related]  

  • 17. Financial Times Global Pharmaceutical & Biotechnology Conference 2009.
    Scattereggia J
    IDrugs; 2010 Jan; 13(1):26-9. PubMed ID: 20024844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Troubled UK biotech firm faces new probe.
    Masood E
    Nature; 1998 Apr; 392(6679):852. PubMed ID: 9582060
    [No Abstract]   [Full Text] [Related]  

  • 19. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 20. Michigan's next wave of biopharmaceutical entrepreneurship.
    Kerppola R; van de Walle M; Surine S
    Nat Biotechnol; 2003 Sep; 21(9):1109-11. PubMed ID: 12949575
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.